OverviewSuggest Edit
Moderna is a biotechnology company that develops therapeutics and vaccines. It provides medicine for treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. The company caters to the healthcare sector.
| Type | Public | |
| Founded | 2010 | |
| HQ | Cambridge, MA, US | Map |
| Website | modernatx.com | |
| Employee Ratings | More | |
| Overall Culture | D- | More |
Recent NewsAll News
- Moderna would never release coronavirus vaccine data different from 'reality,' chairman says
- Morgan Stanley now sees Moderna shares spiking 26% from current levels, cites 65% chance of success for virus vaccine (MRNA)
- Lonza CEO says on pace to make Moderna trial vaccine in June/July - CNBC
- Dow futures struggle for direction Tuesday evening after Moderna vaccine report sparks Dow's 390-point skid
Key People/Management at Moderna
Stephen Hoge
President
Noubar Afeyan
Co-founder and Chairman
Stephane Bancel
Chief Executive Officer, Board Member
Juan Andres
Chief Technical Operations and Quality Officer
Paul Burton
Chief Medical Officer
Marcello Damiani
Chief Digital and Operational Excellence Officer
Moderna Office Locations
Moderna has offices in Cambridge and Norwood
Cambridge, MA, US (HQ)
200 Technology Square
Norwood, MA, US
100 Upland Rd
Moderna Financials and Metrics
Moderna Revenue
Moderna's revenue was reported to be $18.47 b in FY, 2021
| USD | |
|---|---|
Revenue (FY, 2021) | 18.5b |
Gross profit (FY, 2021) | 15.9b |
Gross profit margin (FY, 2021), % | 85.8% |
Net income (FY, 2021) | 12.2b |
EBIT (FY, 2021) | 13.3b |
Market capitalization (17-May-2022) | 57.7b |
Closing stock price (17-May-2022) | 142.3 |
Cash (31-Mar-2021) | 5.4b |
EV | 52.5b |
Moderna's current market capitalization is $57.7 b.
Annual
Annual
Annual
Quarterly
| USD | Q3, 2017 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 |
|---|---|---|---|---|---|---|---|---|---|
Net Income | (243.3m) | (218.0m) | (132.7m) | (267.7m) | (390.9m) | (124.2m) | (240.9m) | (474.6m) | 1.2b |
Depreciation and Amortization | 58.4m | 43.6m | 7.3m | 14.8m | 22.1m | 15.0m | 15.0m | ||
Inventories | (448.0m) | ||||||||
Accounts Payable | 718.0k | (9.9m) | 1.7m | (1.5m) | (19.2m) | 2.3m | 11.5m | 13.6m | (15.0m) |
| USD | FY, 2016 |
|---|---|
Financial Leverage | -4.2 x |
Moderna Operating Metrics
Moderna's Clinical Programs was reported to be 10 in Q3, 2018.
Moderna Acquisitions / Subsidiaries
| Company Name | Date | Deal Size |
|---|---|---|
| Brizo Ltd. | ||
| Moderna Australia Pty Ltd | ||
| Moderna Austria GmbH | ||
| Moderna Biopharma Canada Corporation | ||
| Moderna Biotech Ireland Limited | ||
| Moderna Biotech Securities, Inc. | ||
| Moderna Biotech Spain, S.L.U. | ||
| Moderna Biotech UK Limited | ||
| Moderna Charitable Foundation, Inc. | ||
| Moderna France |
Moderna Revenue Breakdown
Moderna revenue breakdown by business segment: 95.7% from Product Sales and 4.3% from Other
Moderna revenue breakdown by geographic segment: 37.1% from Europe, 29.5% from Rest of World and 33.4% from United States
Moderna Cybersecurity Score
Moderna Environment, Social & Governance (ESG) Ratings
Moderna Online and Social Media Presence
147.09k Twitter followers
Moderna has 147.09k Twitter Followers. The number of followers has increased 0.3% month over month and increased 2.1% quarter over quarter
Moderna's Trends
Twitter Engagement Stats for @moderna_tx
1.8k
Tweets
512
Following
147.1k
Followers
56
Tweets last 30 days
82.2
Avg. likes per Tweet
100%
Tweets with engagement
Moderna Company Culture
Overall Culture
D-
51/100
CEO Rating
D
60/100
Compensation
C+
73/100
Moderna News and Updates
May 20, 2020
Moderna would never release coronavirus vaccine data different from 'reality,' chairman says
The company put out the extent of data it had available, Moderna Chairman Noubar Afeyan tells CNBC.
May 20, 2020
Morgan Stanley now sees Moderna shares spiking 26% from current levels, cites 65% chance of success for virus vaccine (MRNA)
Morgan Stanley raised its Moderna price target to $90 from $37, citing "initial promising Covid-19 vaccine data," according to a Wednesday note.
That's a 26% jump from where shares of Moderna currently trade.
The bank risk-adjusted its estimates following the early results of the vaccine and no…
May 20, 2020
Lonza CEO says on pace to make Moderna trial vaccine in June/July - CNBC
Contract drug manufacturer Lonza
still expects to supply drugmaker Moderna with
active ingredients for its experimental COVID-19 vaccine by June
or July to support laboratory trials, the Swiss company's
interim CEO, Albert Baehny, told CNBC on Wednesday.
May 19, 2020
Dow futures struggle for direction Tuesday evening after Moderna vaccine report sparks Dow's 390-point skid
U.S. stock-index futures ticked higher in thinly traded bumpy action Tuesday evening after the Dow snapped a three-session win streak in the last hour of the regular session, following a report that cast doubt on a coronavirus remedy. Futures for the Dow Jones Industrial Average rose 0.2% at 24,194…
May 19, 2020
Scientists Raise Questions About Moderna Vaccine In Market-Shaking Report
They have to publish a scientific paper, opting for issuing press releases instead.
May 19, 2020
Stocks making the biggest moves after hours: Urban Outfitters, Moderna, Johnson & Johnson and more
Check out the companies making headlines after the bell.
Moderna Blogs
March 16, 2020
Moderna Announces First Participant Dosed in NIH-led Phase 1 Study of mRNA Vaccine (mRNA-1273) Against Novel Coronavirus
Moderna Announces First Participant Dosed in NIH-led Phase 1 Study of mRNA Vaccine (mRNA-1273) Against Novel Coronavirus
Content Import
Mon, 03/16/2020 - 12:42
Moderna Announces First Participant Dosed in NIH-led Phase 1 Study of mRNA Vaccine (mRNA-1273) Against Novel Coronavirus
…
March 11, 2020
Modified mRNA/lipid nanoparticle-based vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective in rodent models of RSV infection
This pre-clinical study shows that an mRNA RSV vaccine elicited both neutralizing antibodies and robust cellular immune response in rodent models of RSV infection and suggests mRNA vaccines may improve immune responses through presentation of antigens that better mimics what is observed during natu…
March 11, 2020
Disease pharmacokinetic‐pharmacodynamic modelling in acute intermittent porphyria to support the development of mRNA‐based therapies
This publication outlines a translational modeling framework that can be used to describe the effects of mRNA therapy for acute intermittent porphyria (AIP) in preclinical models and support development in humans.
Publication Date:
Wednesday, March 11, 2020
Is Featured:
Modalties:
Systemic Ther…
March 03, 2020
Moderna Completes Enrollment of Cytomegalovirus (CMV) Vaccine (mRNA-1647) Phase 2 Study
Phase 2 interim data at three months, expected in 3Q 2020, intended to inform Phase 3 dose selection Pivotal Phase 3 study manufacturing and planning underway; study start expected in 2021 CMV is the most common infectious cause of birth defects in the U.S.
March 03, 2020
Moderna Announces Updated Plans for its March 4 Manufacturing & Digital Day Event
Moderna Announces Updated Plans for its March 4 Manufacturing & Digital Day Event
Content Import
Mon, 03/02/2020 - 19:37
Moderna Announces Updated Plans for its March 4 Manufacturing & Digital Day Event
March 2, 2020 at 7:37 PM EST
This release is a ba…
February 26, 2020
Moderna to Host Manufacturing & Digital Day on March 4, 2020
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 26, 2020-- Moderna, Inc. , (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it will host a Manufacturing
Moderna Frequently Asked Questions
When was Moderna founded?
Moderna was founded in 2010.
Who are Moderna key executives?
Moderna's key executives are Stephen Hoge, Noubar Afeyan and Stephane Bancel.
How many employees does Moderna have?
Moderna has 2,700 employees.
What is Moderna revenue?
Latest Moderna annual revenue is $18.5 b.
What is Moderna revenue per employee?
Latest Moderna revenue per employee is $6.8 m.
Who are Moderna competitors?
Competitors of Moderna include Celyad, CureVac and Regulus Therapeutics.
Where is Moderna headquarters?
Moderna headquarters is located at 200 Technology Square, Cambridge.
Where are Moderna offices?
Moderna has offices in Cambridge and Norwood.
How many offices does Moderna have?
Moderna has 2 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies